The HOXC‐AS2/miR‐876‐5p/HKDC1 axis regulates endometrial cancer progression in a high glucose‐related tumor microenvironment

Xiugui Sheng · 2022-05-29

Abstract

The tumor microenvironment (TME) is related to chronic inflammation and is currently identified as a risk factor for the occurrence and development of endometrial cancer (EC). Pyroptosis is a new proinflammatory form of programmed cell death that plays a critical role in the progression of multiple diseases. However, the important role of pyroptosis in high‐glucose (HG)‐related EC and the underlying molecular mechanisms remain elusive. In the present study, transcriptome high‐throughput sequencing revealed significantly higher hexokinase domain‐containing 1 (HKDC1) expression in EC patients with diabetes than in EC patients with normal glucose. Mechanistically, HKDC1 regulates HG‐induced cell pyroptosis by modulating the production of reactive oxygen species and pyroptosis‐induced cytokine release in EC. In addition, HKDC1 regulates TME formation by enhancing glycolysis, promoting a metabolic advantage in lactate‐rich environments to further accelerate EC progression. Subsequently, miR‐876‐5p was predicted to target the HKDC1 mRNA, and HOXC‐AS2 was identified to potentially inhibit the miR‐876‐5p/HKDC1 axis in regulating cell pyroptosis in HG‐related EC. Collectively, we elucidated the regulatory role of the HOXC‐AS2/miR‐876‐5p/HKDC1 signal transduction axis in EC cell pyroptosis at the molecular level, which may provide an effective therapeutic target for patients with diabetes who are diagnosed with EC.

Funding

Taishan Scholars

ts201511073

Shenzhen Healthcare Research Project

SZLY2017030

Special Fund for Scientific Talents of the First Affiliated Hospital of Xiamen University

ZLYY201906

Sanming Project of Medicine in Shenzhen

SZSM201812075

Xiamen Medical and Health Guiding Project Fund Project

3502Z20214ZD1020

National Natural Science Foundation of China

NSFC81672591

National Major Scientific and Technological Special Project for "Significant New Drugs Development"

2020ZX09201005

Fujian Natural Science Foundation (Youth Innovation) Project

2020J05308